CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca Pharmaceuticals LP v. Glenmark Generics Inc. USA

1:10-cv-00543

Overview

Case Number 1:10-cv-00543
Filing Date 2010-06-21
Status Terminated
Termination Date 2012-03-22
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Glenmark Generics Inc. USA Operating Company

Represented By

2 Attorneys Listed

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Sarah R. Stafford

Benesch Friedlander Coplan & Aronoff

Benesch Friedlander Coplan & Aronoff, 222 Delaware Ave, Ste. 801

Plaintiff

Shionogi Seiyaku Kabushiki Kaisha Operating Company

Represented By

1 Attorneys Listed

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

IPR Pharmaceuticals Inc. Operating Company

Represented By

1 Attorneys Listed

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

AstraZeneca UK Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

AstraZeneca Pharmaceuticals, LP NPE (Individual / Inventor)

Represented By

1 Attorneys Listed

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
USRE37314
Pyrimidine derivatives
Filed: 1998-08-27
Issued: 2001-08-07
Expired (Term Ended)
Expires: 2016-01-08

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

10

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Procedural / Extension Motion 10

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 14 STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to November 12, 2010 filed by Glenmark Generics Inc...
Entry #— • 2010-10-18
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to November 12, 2010 - filed by Glenmark Generics Inc. USA. (Gaza, An...
Entry #14 • 2010-10-15 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 13 STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to October 15, 2010 -- Reset Answer Deadline: Glenm...
Entry #— • 2010-10-01
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to October 15, 2010 - filed by Glenmark Generics Inc. USA. (Gaza, Ann...
Entry #13 • 2010-09-30 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 12 STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to October 1, 2010 filed -- Reset Answer Deadline: ...
Entry #— • 2010-09-13
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move or otherwise plead in response to the Complaint to October 1, 2010 - filed by Glenmark Generics Inc. USA. (Gaza, Anne...
Entry #12 • 2010-09-10 Document →

Docket Entries

(31 total)
Pleading / Complaint

COMPLAINT filed against Glenmark Generics Inc. USA - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 0311-749605.) - filed by AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Shionogi Seiyaku Kabushiki Kaisha, IPR Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(ksr) (Entered: 06/22/2010)

Entry #1 • 2010-06-21
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (ksr) (Entered: 06/22/2010)

Entry #2 • 2010-06-21
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US RE37,314 E; (ksr) (Entered: 06/22/2010)

Entry #3 • 2010-06-21
1

Summons Issued as to Glenmark Generics Inc. USA on 6/21/2010. (ksr)

Entry #4 • 2010-06-21
1
No Actions
Pleading / Complaint

SUMMONS Returned Executed by AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Shionogi Seiyaku Kabushiki Kaisha, IPR Pharmaceuticals Inc.. Glenmark Generics Inc. USA served on 6/22/2010, answer due 7/13/2010. (Bourke, Mary) (Entered: 06/24/2010)

Entry #4 • 2010-06-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc